In mouse models, a novel hepatokine called SDC4 responds to exercise and reduces fatty acid uptake and liver steatosis, offering potential insights into novel targets for NAFLD treatment by elucidating the proteome alterations in hepatocytes due to exercise [33]. The gene discussed is SDC4; the disease is fatty liver disease.